Arq, Inc. heads into its May 7 earnings print with a notable insider buying cluster that sharply contrasts the stock's recent selloff.
The post-earnings wreckage from March sets the scene. The last quarterly print sent ARQ down 44% in a single session, and the stock dropped another 40% over the following five days — one of the steepest single-quarter reactions in the specialty chemicals space. Shares have since recovered partially to $2.31, but are still down roughly 6% over the past month. That brutal drawdown is the backdrop against which a cluster of insiders chose to buy.
The buying response to that collapse was unusually broad. Director Richard Campbell-Breeden purchased 150,000 shares at roughly $2.21, committing $332,000 of personal capital within days of the March drop. Independent Director Carol Eicher added 77,500 shares at around $1.95 for approximately $151,000. The CTO and the General Counsel both made smaller open-market purchases. Over the 90 days to March 23, net insider activity totals roughly 313,000 shares bought for $729,000 in net value. That kind of multi-executive buying at post-crash prices reflects genuine conviction that the sell-off overshot.
Short positioning tells a calmer story than the March volatility might imply. Short interest has eased nearly 10% over the past month to 3.7% of the free float — a moderate level, not extreme. Borrow remains cheap at 0.56%, and borrow availability is wide, meaning there is no meaningful squeeze pressure in the lending market. The ORTEX short score has also drifted lower from above 40 to 37, consistent with shorts gradually reducing exposure after the March drop. Options positioning is skewed overwhelmingly toward calls: the put/call ratio of 0.04 sits well above its 20-day average but remains among the lowest readings of the past year, signalling that options buyers are not bracing defensively into this print.
Analyst coverage has been resilient in direction but pessimistic on price. Canaccord Genuity and Clear Street both maintained Buy ratings following the March collapse while cutting targets sharply — Canaccord moved from $7.50 to $5.00, Clear Street from $8.00 to $6.50. Both notes were filed in mid-March, making them roughly eight weeks old. At $2.31, the stock trades at a steep discount to even the reduced consensus target of $3.63, implying the Street sees substantial upside — but also that the market is unconvinced. Estimated revenue runs near $123 million with positive operating cash flow, yet the company still posts a net loss and carries $24 million in net debt. The EV/EBITDA multiple has compressed to around 7x, a low reading that reflects the market's scepticism about whether ARQ can convert improving cash flow into sustained profitability.
Today's print is therefore less about the size of the revenue line and more about whether management can demonstrate that the March guidance miss was an anomaly — and whether the insiders who stepped in at post-crash prices were reading the fundamentals correctly.
See the live data behind this article on ORTEX.
Open ARQ on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
